Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules - 15/01/16
Abstract |
Background |
Radiotherapy is an established treatment for some types of patients with nonmelanoma skin cancer. A hypofractionated schedule has been proposed as a valuable option for elderly disabled patients to minimize the number of hospital visits.
Objective |
We sought to compare a weekly hypofractionated orthovoltage radiotherapy regimen with a standard daily one for the treatment of nonmelanoma skin cancer.
Methods |
A retrospective cohort study was performed on 436 tumors. Overall survival, disease-free survival, and cosmetic outcome were measured. Life-table analysis, Kaplan-Meier survival analysis, and multivariate Cox regression model were performed.
Results |
The hypofractionated regimen was not associated with increased recurrence rates and mortality, or with a poorer cosmetic outcome, when compared with the daily schedule.
Limitations |
Absence of complete information about acute treatment toxicity and a shorter follow-up time for patients receiving the weekly schedule are limitations of this study.
Conclusions |
A weekly hypofractionated regimen of orthovoltage radiotherapy seems to be the most appropriate approach in elderly disabled patients with nonmelanoma skin cancers.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, keratinocyte carcinoma, radiotherapy, skin cancer, squamous cell carcinoma, therapy
Abbreviations used : BCC, DFS, NMSC, OS, SCC
Plan
| Drs Palmieri and Kyrgidis contributed equally to this work. |
|
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 74 - N° 2
P. 341-347 - février 2016 Retour au numéro
Article précédent
- Other primary systemic cancers in patients with melanoma: Analysis of balanced acral and nonacral melanomas
- Soo Hyeon Bae, Hyun Ju Seon, Yoo Duk Choi, Hyun-Jeong Shim, Jee-Bum Lee, Sook Jung Yun
- Microneedling in skin of color: A review of uses and efficacy
- Brandon E. Cohen, Nada Elbuluk
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?